Spirulina Gastric Emptying Breath Test
Commercial- Indications
- Gastroparesis
Company intelligence / Profile preview
Cairn Diagnostics
Brentwood, Tennessee, United Statescairndiagnostics.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Cairn Diagnostics has developed and commercialized the FDA-approved 13C-Spirulina Gastric Emptying Breath Test (GEBT), a non-invasive, non-radioactive diagnostic for gastroparesis. The GEBT is validated against gastric scintigraphy and can be administered in clinical settings or at home via telehealth. Clinical studies reported no deaths or serious adverse events; some participants experienced mild discomfort. The test is covered by Medicare and recommended by the American College of Gastroenterology.
- Therapeutic areas
- Gastroenterology
- Modalities
- DeviceNon-pharmacological therapyDiagnostic test
- Industry
- Metabolite Diagnostics
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Cairn Diagnostics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cairn Diagnostics.